HIMS INVESTOR ALERT: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims related to deceptive practices in promoting and selling medications [1][2][3] Group 1: Lawsuit Details - The class action lawsuit, titled Sookdeo v. Hims & Hers Health, Inc., involves purchasers of Hims & Hers securities from April 29, 2025, to June 23, 2025, with a deadline of August 25, 2025, for seeking lead plaintiff status [1][4] - Allegations include that Hims & Hers engaged in deceptive promotion and selling of illegitimate versions of Wegovy®, which jeopardized patient safety [2][3] - Following the termination of its partnership with Novo Nordisk due to these allegations, Hims & Hers' stock price dropped by over 34% [3] Group 2: Company Background - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2] - The company announced a collaboration with Novo Nordisk on April 29, 2025, which was later terminated due to the aforementioned allegations [2][3] Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in this class action lawsuit and is recognized as a leading law firm in securities fraud and shareholder litigation [5] - The firm has a strong track record, having recovered over $2.5 billion for investors in 2024 alone, and has been ranked 1 in securing monetary relief for investors [5]